KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $16.6 million.

  • CRISPR Therapeutics AG's Share-based Compensation fell 2292.62% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.4 million, marking a year-over-year decrease of 799.25%. This contributed to the annual value of $86.6 million for FY2024, which is 687.66% up from last year.
  • According to the latest figures from Q3 2025, CRISPR Therapeutics AG's Share-based Compensation is $16.6 million, which was down 2292.62% from $17.6 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Share-based Compensation ranged from a high of $28.3 million in Q2 2021 and a low of $16.6 million during Q3 2025
  • For the 5-year period, CRISPR Therapeutics AG's Share-based Compensation averaged around $22.2 million, with its median value being $22.0 million (2024).
  • In the last 5 years, CRISPR Therapeutics AG's Share-based Compensation soared by 8048.67% in 2021 and then crashed by 2562.1% in 2025.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Share-based Compensation stood at $25.8 million in 2021, then dropped by 11.53% to $22.8 million in 2022, then fell by 19.23% to $18.4 million in 2023, then increased by 19.33% to $22.0 million in 2024, then fell by 24.46% to $16.6 million in 2025.
  • Its Share-based Compensation stands at $16.6 million for Q3 2025, versus $17.6 million for Q2 2025 and $20.2 million for Q1 2025.